Junshi Biosciences Announces Completion of Enrollment in Phase I Trial of SARS-CoV-2 Neutralizing Antibody JS016 in China
July 12, 2020 20:00 ET
|
Junshi Biosciences
SHANGHAI, China, July 12, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
C-Bond Systems Receives Initial Purchase Order for MB-10 Tablets in Excess of $80,000 from Southeast Asian Distributor
July 08, 2020 08:31 ET
|
C-Bond Systems
HOUSTON, July 08, 2020 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, announced today that it has received an initial purchase order...
In Vitro Testing of Innovation Pharmaceuticals’ Brilacidin for COVID-19 Shows Consistent Anti-SARS-CoV-2 Efficacy; Manufacturing Preparation Underway for COVID-19 Clinical Trial
July 07, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today reports the latest developments related...
Digital Ally Announces Launch of its Shield™ Cleansers E-commerce Website
July 06, 2020 08:42 ET
|
Digital Ally Inc.
Launch of site now enables both online and traditional ordering options in response to high demand for its Shield brand of highly effective, less-harsh, disinfectant and cleanser line Lenexa,...
Pfizer und BioNTech veröffentlichen erste positive Daten aus laufender Phase-1/2-Studie mit mRNA-basiertem SARS-CoV-2-Impfstoffkandidaten
July 01, 2020 09:01 ET
|
BioNTech SE
In der laufenden verblindeten, Placebo-kontrollierten Phase-1/2-Studie in den USA wird ein nukleosidmodifizierter messenger-RNA-Impfstoffkandidat (BNT162b1), der für die Rezeptorbindungsdomäne (RBD)...
Pfizer and BioNTech Announce Early Positive Data from an Ongoing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-CoV-2
July 01, 2020 09:01 ET
|
BioNTech SE
In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD)...
Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients
June 23, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
Sanofi and Translate Bio Expand Collaboration to Develop mRNA Vaccines Across All Infectious Disease Areas
June 23, 2020 00:59 ET
|
Translate Bio, Inc.
-- The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases -- -- Translate Bio to receive...
Innovation Pharmaceuticals’ Brilacidin Inhibits SARS-CoV-2 (COVID-19) by 97 Percent in a Human Lung Cell Line
June 17, 2020 07:30 ET
|
Innovation Pharmaceuticals Inc.
Data From Ongoing Testing at U.S. Regional Biocontainment Laboratory Data adds to growing body of research in both human and animal cell lines supporting Brilacidin’s robust antiviral properties...
Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19
June 16, 2020 08:19 ET
|
Biomerica, Inc.
This high-volume laboratory test will allow for collection of blood samples using a simplified proprietary blood collection device once cleared by the FDA. This test adds to the previously announced...